Pharma and biotech companies are hoping for a recovery in R&D productivity to replace aging blockbusters. But any rebound in new product approvals will have to wait until the research drought is over. It's as hard as ever to find agents near launch that might make a commercial impact. Among the blue-chip launch prospects are two for treating patients with malignant melanoma: ipilimumab, the Bristol-Myers Squibb monoclonal antibody, and PLX 4032, the Roche/Plexxikon BRAF inhibitor. In the metabolic category, a new oral class of diabetes meds is gaining steam, the SGLT2 inhibitors. Another long-shot, but one with huge potential, hails from the cardiovascular area. Finally, two holdovers from last year's Pipeline Report, the hepatitis C therapies telaprevir and boceprevir, have analysts crowing.